Cargando…

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis

BACKGROUND: Systemic inflammation plays an important role in the increased cardiac risk observed in rheumatoid arthritis (RA). Effective control of inflammation and disease activity may be of benefit in reducing cardiovascular risk in RA patients. OBJECTIVE: Our study was conducted in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Sylvain, Couderc, Marion, Glace, Baptiste, Pereira, Bruno, Tournadre, Anne, Dubost, Jean-Jacques, Soubrier, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854916/
https://www.ncbi.nlm.nih.gov/pubmed/24324327
http://dx.doi.org/10.2147/BTT.S52003
_version_ 1782294875521155072
author Mathieu, Sylvain
Couderc, Marion
Glace, Baptiste
Pereira, Bruno
Tournadre, Anne
Dubost, Jean-Jacques
Soubrier, Martin
author_facet Mathieu, Sylvain
Couderc, Marion
Glace, Baptiste
Pereira, Bruno
Tournadre, Anne
Dubost, Jean-Jacques
Soubrier, Martin
author_sort Mathieu, Sylvain
collection PubMed
description BACKGROUND: Systemic inflammation plays an important role in the increased cardiac risk observed in rheumatoid arthritis (RA). Effective control of inflammation and disease activity may be of benefit in reducing cardiovascular risk in RA patients. OBJECTIVE: Our study was conducted in patients with active RA to investigate the effects of 24-week abatacept treatment on aortic stiffness measured by pulse wave velocity (PWV). RESULTS: The study included 21 patients, of whom 17 were females, with a mean age of 65.2±13.7 years. Ten patients had positive rheumatoid factors, 16 positive anti-citrullinated protein antibodies, and 19 presented an erosive form of RA. Sixteen patients were nonresponders to anti-tumor necrosis factor-alpha treatments. After 6 months of abatacept treatment, there was a significant increase in PWV levels (9.8±2.9 versus 8.5±3.9 m/second; P=0.02). A nonsignificant increase in total cholesterol and low-density lipoprotein cholesterol was observed. There was also a significant increase in high-density lipoprotein cholesterol levels, which led to a nonsignificant decrease in atherogenic index. The improvement in disease activity was significant, and there was a decrease of systemic inflammatory parameters, but without reaching statistical significancy. Changes in PWV were significantly correlated with changes in Disease Activity Score on 28 joints based on erythrocyte sedimentation rate (r=0.46; P=0.035) and in high-density lipoprotein cholesterol (r=−0.38; P=0.046). No correlation was observed with changes in C-reactive protein and in other parameters of lipid profile or in steroid dose. CONCLUSION: The worsening of aortic stiffness found after 6 months of abatacept therapy might be due to an insufficient decrease in systemic inflammation.
format Online
Article
Text
id pubmed-3854916
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38549162013-12-09 Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis Mathieu, Sylvain Couderc, Marion Glace, Baptiste Pereira, Bruno Tournadre, Anne Dubost, Jean-Jacques Soubrier, Martin Biologics Original Research BACKGROUND: Systemic inflammation plays an important role in the increased cardiac risk observed in rheumatoid arthritis (RA). Effective control of inflammation and disease activity may be of benefit in reducing cardiovascular risk in RA patients. OBJECTIVE: Our study was conducted in patients with active RA to investigate the effects of 24-week abatacept treatment on aortic stiffness measured by pulse wave velocity (PWV). RESULTS: The study included 21 patients, of whom 17 were females, with a mean age of 65.2±13.7 years. Ten patients had positive rheumatoid factors, 16 positive anti-citrullinated protein antibodies, and 19 presented an erosive form of RA. Sixteen patients were nonresponders to anti-tumor necrosis factor-alpha treatments. After 6 months of abatacept treatment, there was a significant increase in PWV levels (9.8±2.9 versus 8.5±3.9 m/second; P=0.02). A nonsignificant increase in total cholesterol and low-density lipoprotein cholesterol was observed. There was also a significant increase in high-density lipoprotein cholesterol levels, which led to a nonsignificant decrease in atherogenic index. The improvement in disease activity was significant, and there was a decrease of systemic inflammatory parameters, but without reaching statistical significancy. Changes in PWV were significantly correlated with changes in Disease Activity Score on 28 joints based on erythrocyte sedimentation rate (r=0.46; P=0.035) and in high-density lipoprotein cholesterol (r=−0.38; P=0.046). No correlation was observed with changes in C-reactive protein and in other parameters of lipid profile or in steroid dose. CONCLUSION: The worsening of aortic stiffness found after 6 months of abatacept therapy might be due to an insufficient decrease in systemic inflammation. Dove Medical Press 2013 2013-12-02 /pmc/articles/PMC3854916/ /pubmed/24324327 http://dx.doi.org/10.2147/BTT.S52003 Text en © 2013 Mathieu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Mathieu, Sylvain
Couderc, Marion
Glace, Baptiste
Pereira, Bruno
Tournadre, Anne
Dubost, Jean-Jacques
Soubrier, Martin
Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_full Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_fullStr Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_full_unstemmed Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_short Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
title_sort effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854916/
https://www.ncbi.nlm.nih.gov/pubmed/24324327
http://dx.doi.org/10.2147/BTT.S52003
work_keys_str_mv AT mathieusylvain effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
AT coudercmarion effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
AT glacebaptiste effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
AT pereirabruno effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
AT tournadreanne effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
AT dubostjeanjacques effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis
AT soubriermartin effectsof6monthsofabatacepttreatmentonaorticstiffnessinpatientswithrheumatoidarthritis